InvestorWire NewsRoom

Articles

Articles Category: Biotechnology
Home / InvestorWire NewsRoom / Articles / Articles Category: Biotechnology
Monday Nov 16, 2020 - 12:28 pm

Predictive Oncology (NASDAQ: POAI) CEO Discusses Subsidiaries’ Proprietary Tech, Innovative Media

CEO expects results that will “build the stock and raise the stock price”POAI focused on positioning TumorGenesis kits to manufacturersHelomics has largest database of its kind in the world, brings cutting-edge technology to cancer research During a recent NetworkNewsWire exclusive audio interview, Predictive Oncology (NASDAQ: POAI) CEO Carl Schwartz noted recent company milestones and outlined strategic goals. In addition, Schwartz provided key updates on the…

Continue Reading

Wednesday Nov 11, 2020 - 2:12 pm

Predictive Oncology (NASDAQ: POAI) CEO Joins NNW Podcast to Discuss Company’s Prospects; Provides Update on POAI Subsidiaries

Predictive Oncology CEO Carl Schwartz featured on NNW’s podcast to discuss the company’s prospectsSchwartz elaborated on company’s various divisions, affirming that POAI had begun to see revenue trends stabilize, cash burn rates declineTumorGenesis received overwhelmingly positive feedback on its initial product launches, with plans to extend its technological prowess to address other oncological segmentsSoluble Biotech, which announced its first major contract in August, is expected…

Continue Reading

Friday Nov 06, 2020 - 1:37 pm

Predictive Oncology (NASDAQ: POAI) Subsidiary’s HSC Technology Optimization Solution Offers Unparalleled Results, Benefits

POAI subsidiary Soluble Biotech’s optimization solution shaves time and cost off of traditional options offered by competitionResults garnered from company’s HSC optimization are unparalleled in fieldSoluble Biotech lands first major contract, signifying major company milestone Offering a proprietary automated High Throughput Self-Interaction Chromatography(TM) (“HSC”) Technology Platform, Predictive Oncology (NASDAQ: POAI) provides biomedical and pharmaceutical companies with superior options never before available. A knowledge-driven company focused…

Continue Reading

Thursday Nov 05, 2020 - 2:23 pm

VistaGen Therapeutics’ (NASDAQ: VTGN) New Generation Phase 3 Drug Candidate for Social Anxiety Disorder Gains Importance Amid FDA Wariness of Benzodiazepines

VistaGen has three innovative CNS drug candidates which target a wide range of anxiety, depression and neurological disordersPH94B, the Company’s most advanced drug candidate, is entering Phase 3 development for acute, on-demand treatment of social anxiety disorderCompany sees potential to displace benzodiazepines currently being used to treat multiple anxiety disordersStrategy has gained in importance after U.S. FDA announced in late-September its update requirement for boxed…

Continue Reading

Wednesday Nov 04, 2020 - 3:07 pm

Brain Scientific Inc. (BRSF) Is ‘One to Watch’

Brain Scientific is a commercial-stage health care company aiming to modernize the brain diagnostics market by employing cutting edge technologies to bridge the widening gap in access to neurological careThe company’s current offerings are the NeuroCap(TM) and NeuroEEG(TM) – two FDA-cleared devices delivered by wholly owned subsidiary MemoryMD Inc.The company’s intellectual property portfolio includes three patents in the U.S., China and EuropeBrain Scientific is developing…

Continue Reading

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).